Novartis and the spin-off of Sandoz: strategic insights and visions for the future by Jana Petek
Corporate mergers often attract attention, but it’s the demergers of companies that grab the public’s curiosity. Such was the case with the separation of Novartis and Sandoz last year
To illustrate the impact of this decisive move, IMB welcomed Jana Petek, former CEO and current Global Head of TechOps at Novartis, as a guest speaker.
Petek emphasized Novartis’ strategic aim to enhance its global market position and accelerate the development of innovative therapies. The separation, she explained, positions the company to lead the pharmaceutical industry’s future, focusing on addressing critical global health challenges.
The IMB students sincerely thank Ms. Petek for her valuable insights.